

**ANNEX I**

**SUMMARY OF PRODUCT CHARACTERISTICS**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Cortavance 0.584 mg/ml cutaneous spray solution for dogs

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

### Active substance:

Hydrocortisone aceponate      0.584 mg

### Excipient:

Qualitative composition of excipients and other constituents
Propylene glycol methyl ether

Clear colourless or very slightly yellow solution.

## 3. CLINICAL INFORMATION

### 3.1 Target species

Dogs.

### 3.2 Indications for use for each target species

For symptomatic treatment of inflammatory and pruritic dermatoses in dogs.  
For alleviation of clinical signs associated with atopic dermatitis in dogs.

### 3.3 Contraindications

Do not use on cutaneous ulcers.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

### 3.4 Special warnings

None.

### 3.5 Special precautions for use

#### Special precautions for safe use in the target species:

Clinical signs of atopic dermatitis such as pruritus and skin inflammation are not specific for this disease and therefore other causes of dermatitis such as ectoparasitic infestations and infections which cause dermatological signs should be ruled out before treatment is started, and underlying causes should be investigated.

In the case of concurrent microbial disease or parasitic infestation, the dog should receive appropriate treatment for such condition.

In the absence of specific information, the use in animal suffering from Cushing's syndrome shall be based on the risk-benefit assessment.

Since glucocorticosteroids are known to slow growth, use in young animals (under 7 months of age) shall be based on the risk-benefit assessment and subject to regular clinical evaluations.

Total body surface treated should not exceed approximately 1/3 of the dog's surface corresponding for example to a treatment of two flanks from the spine to the mammary chains including the shoulders and the thighs (see also section 3.10). Otherwise, use only according to the risk-benefit assessment of the responsible veterinary surgeon and subject the dog to regular clinical evaluations as further described in section 3.9.

Care should be taken to avoid spraying into the eyes of the animal.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

The active substance is potentially pharmacologically active at high doses of exposure.  
The formulation may cause eye irritation following accidental ocular contact.  
The formulation is flammable.

Wash hands after use. Avoid contact with eyes.  
To avoid skin contact, recently treated animals should not be handled until the application site is dry.  
To avoid inhalation of the product, apply the spray in a well-ventilated area.  
Do not spray on naked flame or any incandescent material.  
Do not smoke while handling the veterinary medicinal product.  
Replace the bottle in the outer carton and in a safe place out of the sight and the reach of children immediately after use.

In case of accidental skin contact, avoid hand-to-mouth contact and wash the exposed area immediately with water.

In case of accidental eye contact, rinse with abundant quantities of water.

If eye irritation persists, seek medical advice.

In case of accidental ingestion, especially by children, seek medical advice immediately and show the leaflet or the label to the physician.

Special precautions for the protection of the environment:

Not applicable.

Other precautions:

The solvent in this product may stain certain materials including painted, varnished or other household surfaces or furnishings. Allow the application site to dry before permitting contact with such materials.

### 3.6 Adverse events

Dogs:

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Application site pruritus <sup>1</sup> Application site erythema <sup>1</sup>
--	--

<sup>1</sup>Transient local

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing

authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### **3.7 Use during pregnancy, lactation or lay**

The safety of the veterinary medicinal product has not been established during pregnancy and lactation.

Systemic absorption of hydrocortisone aceponate being negligible, it is unlikely for teratogenic, foetotoxic, maternotoxic effects to happen at the recommended dosage in dogs.

#### Pregnancy and lactation:

Use only according to the benefit-risk assessment by the responsible veterinarian.

### **3.8 Interaction with other medicinal products and other forms of interaction**

No data available.

In the absence of information, it is recommended not to apply other topical preparations simultaneously on the same lesions.

### **3.9 Administration routes and dosage**

Cutaneous use.

Before administration, screw the pump spray on the bottle.

The veterinary medicinal product is then applied by activating the pump spray, from a distance of about 10 cm of the area to be treated.

The recommended dosage is 1.52 mcg of hydrocortisone aceponate/cm<sup>2</sup> of affected skin per day. This dosage can be achieved with two pump spray activations over a surface to be treated equivalent to a square of 10 cm x 10 cm.

- For treatment of inflammatory and pruritic dermatoses, repeat the treatment daily for 7 consecutive days.

In case of conditions requiring an extended treatment, the responsible veterinarian should subject the use of the veterinary medicinal product to the risk-benefit assessment.

If signs fail to improve within 7 days, treatment should be re-evaluated by the veterinarian.

- For alleviation of clinical signs associated with atopic dermatitis, repeat the treatment daily for at least 14 and up to 28 consecutive days.

An intermediary control by the veterinarian at day 14 should be made to decide if further treatment is needed. The dog should be re-evaluated regularly with regard to hypothalamic-pituitary axis (HPA) suppression or skin atrophy, both being possibly asymptomatic.

Any prolonged use of this product, to control atopy, should be at the benefit risk assessment of the responsible veterinary surgeon. It should take place after a re-evaluation of the diagnosis and also a consideration of the multi-modal treatment plan in the individual animal.

Presented as a volatile spray, this veterinary medicinal product does not require any massage.

### **3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

Tolerance studies of multiple doses were assessed over a period of 14 days in healthy dogs using 3 and 5 times the recommended dosage corresponding to the two flanks, from the spine to the mammary chains including the shoulder and the thighs (1/3 of the dog's body surface area). These resulted in a reduced capacity for production of cortisol that is fully reversible within 7 to 9 weeks after the end of treatment.

In 12 dogs suffering from atopic dermatitis, after topical application once a day at the recommended therapeutic dosage for 28 to 70 (n=2) consecutive days, no noticeable effect on the systemic cortisol level was observed.

### **3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Not applicable.

### **3.12 Withdrawal periods**

Not applicable.

## **4. PHARMACOLOGICAL INFORMATION**

### **4.1 ATCvet code: QD07AC16.**

### **4.2 Pharmacodynamics**

The veterinary medicinal product contains the active substance hydrocortisone aceponate. Hydrocortisone aceponate is a dermocorticoid with a potent intrinsic glucocorticoid activity which means a relief of both inflammation and pruritus leading to a quick improvement of skin lesions observed in case of inflammatory and pruritic dermatosis. In case of atopic dermatitis, improvement will be slower.

### **4.3 Pharmacokinetics**

Hydrocortisone aceponate belongs to the diesters class of the glucocorticosteroids.

The diesters are lipophilic components ensuring an enhanced penetration into the skin associated to a low plasma availability. Hydrocortisone aceponate thus accumulates in the dog's skin allowing local efficacy at low dosage. The diesters are transformed inside the skin structures. This transformation is responsible for the potency of the therapeutic class. In laboratory animals, hydrocortisone aceponate is eliminated the same way as hydrocortisone (other name for endogenous cortisol) through urine and faeces.

Topical application of diesters results in high therapeutic index: high local activity with reduced systemic secondary effects.

## **5. PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

None known.

### **5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.  
Shelf life after first opening the immediate packaging: 6 months.

### **5.3 Special precautions for storage**

This veterinary medicinal product does not require any special storage conditions.

#### **5.4 Nature and composition of immediate packaging**

Box containing a polyethylene terephthalate (PET) or high density polyethylene (HDPE) bottle filled with 31 ml or 76 ml of solution, closed with an aluminium screw cap or a white plastic screw cap and a pump spray.

Carton box with a PET bottle of 31 ml

Carton box with a PET bottle of 76 ml

Carton box with a HDPE bottle of 31 ml

Carton box with a HDPE bottle of 76 ml

Not all pack sizes may be marketed.

#### **5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

### **6. NAME OF THE MARKETING AUTHORISATION HOLDER**

VIRBAC

### **7. MARKETING AUTHORISATION NUMBER(S)**

EU/2/06/069/001

EU/2/06/069/002

EU/2/06/069/003

EU/2/06/069/004

### **8. DATE OF FIRST AUTHORISATION**

Date of first authorisation: 09/01/2007

### **9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

{DD/YYYY}

### **10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

## **ANNEX II**

### **OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

None

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**



## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE****CARTON BOX (31 ml)****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Cortavance 0.584 mg/ml cutaneous spray solution

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each ml contains 0.584 mg of hydrocortisone aceponate

**3. PACKAGE SIZE**

31 ml

**4. TARGET SPECIES**

Dogs.

**5. INDICATIONS****6. ROUTES OF ADMINISTRATION**

Cutaneous use.

**7. WITHDRAWAL PERIOD(S)****8. EXPIRY DATE**

Exp. {mm/yyyy}

Once opened, use by 6 months.

**9. SPECIAL STORAGE PRECAUTIONS****10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

<b>12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”</b>
--

Keep out of the sight and reach of children.

<b>13. NAME OF THE MARKETING AUTHORISATION HOLDER</b>
---

VIRBAC

<b>14. MARKETING AUTHORISATION NUMBERS</b>
--

Carton with a PET bottle of 31 ml: EU/2/06/069/002

Carton with a HDPE bottle of 31 ml: EU/2/06/069/003

<b>15. BATCH NUMBER</b>
-------------------------

Lot {number}

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE****CARTON BOX (76 ml)****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Cortavance 0.584 mg/ml cutaneous spray solution

**2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

Each ml contains 0.584 mg of hydrocortisone aceponate

**3. PACKAGE SIZE**

76 ml

**4. TARGET SPECIES**

Dogs.

**5. INDICATIONS****6. ROUTES OF ADMINISTRATION**

Cutaneous use.

**7. WITHDRAWAL PERIODS****8. EXPIRY DATE**

Exp. {mm/yyyy}

Once opened, use by 6 months.

**9. SPECIAL STORAGE PRECAUTIONS****10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

<b>12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”</b>
--

Keep out of the sight and reach of children.

<b>13. NAME OF THE MARKETING AUTHORISATION HOLDER</b>
---

VIRBAC

<b>14. MARKETING AUTHORISATION NUMBERS</b>
--

Carton box with a PET bottle of 76 ml: EU/2/06/069/001

Carton box with a HDPE bottle of 76 ml: EU/2/06/069/004

<b>15. BATCH NUMBER</b>
-------------------------

Lot {number}

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE****BOTTLE OF 76 ML****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Cortavance 0.584 mg/ml cutaneous spray solution

**2. STATEMENT OF ACTIVE SUBSTANCES**

Hydrocortisone aceponate 0.584 mg/ml

**3. TARGET SPECIES**

Dogs.

**4. ROUTES OF ADMINISTRATION**

Cutaneous use.

Read the package leaflet before use.

**5. WITHDRAWAL PERIODS****6. EXPIRY DATE**

Exp. {mm/yyyy}

Once opened, use by 6 months.

**7. SPECIAL STORAGE PRECAUTIONS****8. NAME OF THE MARKETING AUTHORISATION HOLDER**

VIRBAC

**9. BATCH NUMBER**

Lot {number}

<b>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b> <b>BOTTLE OF 31 ML</b>
---

<b>1. NAME OF THE VETERINARY MEDICINAL PRODUCT</b>
--

Cortavance

<b>2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES</b>
---

0.584 mg/ml

<b>3. BATCH NUMBER</b>
------------------------

Lot {number}

<b>4. EXPIRY DATE</b>
-----------------------

Exp. {mm/yyyy}

## **B. PACKAGE LEAFLET**



## PACKAGE LEAFLET

### **1. Name of the veterinary medicinal product**

Cortavance 0.584 mg/ml cutaneous spray solution for dogs

### **2. Composition**

Hydrocortisone aceponate            0.584 mg/ml

Clear colourless or very slightly yellow solution.

### **3. Target species**

Dogs.

### **4. Indications for use**

For symptomatic treatment of inflammatory and pruritic dermatoses in dogs.

For alleviation of clinical signs associated with atopic dermatitis in dogs.

### **5. Contraindications**

Do not use on cutaneous ulcers.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

### **6. Special warnings**

#### Special precautions for safe use in the target species:

Clinical signs of atopic dermatitis such as pruritus and skin inflammation are not specific for this disease and therefore other causes of dermatitis such as ectoparasitic infestations and infections which cause dermatological signs should be ruled out before treatment is started, and underlying causes should be investigated.

In the case of concurrent microbial disease or parasitic infestation, the dog should receive appropriate treatment for such condition.

In the absence of specific information, the use in animal suffering from Cushing's syndrome shall be based on the risk-benefit assessment.

Since glucocorticosteroids are known to slow growth, use in young animals (under 7 months of age) shall be based on the risk-benefit assessment and subject to regular clinical evaluations.

Total body surface treated should not exceed approximately 1/3 of the dog's surface corresponding for example to a treatment of two flanks from the spine to the mammary chains including the shoulders and the thighs. See also section "Overdose". Otherwise, use only according to the risk-benefit assessment of the responsible veterinary surgeon and subject the dog to regular clinical evaluations as further described in section "Administration routes and dosage".

Care should be taken to avoid spraying into the eyes of the animal.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

The active substance is potentially pharmacologically active at high doses of exposure.  
The formulation may cause eye irritation following accidental ocular contact.  
The formulation is flammable.

Wash hands after use. Avoid contact with eyes.

To avoid skin contact, recently treated animals should not be handled until the application site is dry.

To avoid inhalation of the product, apply the spray in a well-ventilated area.

Do not spray on naked flame or any incandescent material.

Do not smoke while handling the veterinary medicinal product.

Replace the bottle in the outer carton and in a safe place out of the sight and the reach of children immediately after use.

In case of accidental skin contact, avoid hand-to-mouth contact and wash the exposed area immediately with water.

In case of accidental eye contact, rinse with abundant quantities of water.

If eye irritation persists, seek medical advice.

In case of accidental ingestion, especially by children, seek medical advice immediately and show the leaflet or the label to the physician.

Other precautions:

The solvent in this product may stain certain materials including painted, varnished or other household surfaces or furnishings. Allow the application site to dry before permitting contact with such materials.

Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation.

Systemic absorption of hydrocortisone aceponate being negligible, it is unlikely for teratogenic, foetotoxic, maternotoxic effects to happen at the recommended dosage in dogs.

Use only according to the benefit-risk assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:

In the absence of information, it is recommended not to apply other topical preparations simultaneously on the same lesions.

Overdose:

Tolerance studies of multiple doses were assessed over a period of 14 days in healthy dogs using 3 and 5 times the recommended dosage corresponding to the two flanks, from the spine to the mammary chains including the shoulder and the thighs (1/3 of the dog's body surface area). These resulted in a reduced capacity for production of cortisol that is fully reversible within 7 to 9 weeks after the end of treatment.

In 12 dogs suffering from atopic dermatitis, after topical application once a day at the recommended therapeutic dosage for 28 to 70 (n=2) consecutive days, no noticeable effect on the systemic cortisol level was observed.

## **7. Adverse events**

Dogs:

Very rare (<1 animal / 10,000 animals treated, including isolated reports):
Application site pruritus <sup>1</sup> Application site erythema <sup>1</sup>

<sup>1</sup>Transient local

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

## **8. Dosage for each species, routes and method of administration**

Cutaneous use.

Before administration, screw the pump spray on the bottle.

The veterinary medicinal product is then applied by activating the pump spray, from a distance of about 10 cm of the area to be treated.

The recommended dosage is 1.52 mcg of hydrocortisone aceponate/cm<sup>2</sup> of affected skin per day. This dosage can be achieved with two pump spray activations over a surface to be treated equivalent to a square of 10 cm x 10 cm.

- For treatment of inflammatory and pruritic dermatoses, repeat the treatment daily for 7 consecutive days.

In case of conditions requiring an extended treatment, the responsible veterinarian should subject the use of the veterinary medicinal product to the risk-benefit assessment.

If signs fail to improve within 7 days, treatment should be re-evaluated by the veterinarian.

- For alleviation of clinical signs associated with atopic dermatitis, repeat the treatment daily for at least 14 and up to 28 consecutive days.

An intermediary control by the veterinarian at day 14 should be made to decide if further treatment is needed. The dog should be re-evaluated regularly with regard to HPA suppression or skin atrophy, both being possibly asymptomatic.

Any prolonged use of this product, to control atopy, should be at the benefit risk assessment of the responsible veterinary surgeon. It should take place after a re-evaluation of the diagnosis and also a consideration of the multi-modal treatment plan in the individual animal.

## **9. Advice on correct administration**

Presented as a volatile spray, this veterinary medicinal product does not require any massage.

## **10. Withdrawal periods**

Not applicable.

## **11. Special storage precautions**

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

Shelf life after first opening the immediate packaging: 6 months.

## **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

## **13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

## **14. Marketing authorisation numbers and pack sizes**

EU/2/06/069/001-004

### Pack sizes:

Carton box with a PET bottle of 31 ml

Carton box with a PET bottle of 76 ml

Carton box with a HDPE bottle of 31 ml

Carton box with a HDPE bottle of 76 ml

Not all pack sizes may be marketed.

## **15. Date on which the package leaflet was last revised**

{MM/YYYY}

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

## **16. Contact details**

Marketing authorisation holder and manufacturer responsible for batch release:

VIRBAC  
1ère Avenue 2065m LID  
06516 Carros  
France

Local representatives and contact details to report suspected adverse reactions:

**Österreich**

VIRBAC Österreich GmbH  
Hildebrandgasse 27  
A-1180 Wien  
Österreich  
Tel: +43-(0)1 21 834 260

**Република България**

SAM BC EOOD  
Бул. "Д-р Петър Дертлиев" 25, Търговски  
център Лабиринт, ет. 5, офис SAM BC EOOD  
BG София 1335  
Тел: +359 2 810 0173  
sambs@sambs.bg

**Česká republika**

VIRBAC Czech Republic s.r.o.  
Žitavského 496  
156 00 Praha 5  
Česká republika  
Tel.: +420 608 836 529

**Danmark**

VIRBAC Danmark A/S  
Profilvej 1  
6000 Kolding  
Danmark  
Tel: +45 75521244  
virbac@virbac.dk

**España**

VIRBAC España SA  
Angel Guimerá 179-181  
ES-08950 Esplugues de Llobregat (Barcelona)  
España  
Tel.: + 34-(0)93 470 79 40

**France**

VIRBAC France  
13<sup>ème</sup> rue LID  
06517 Carros  
service-conso@virbac.fr

**Hrvatska**

CENTRALNA VETERINARSKA AGENCIJA  
d.o.o. (CVA)  
Prve Ravnice 2e, 10000 Zagreb  
Republika Hrvatska  
Tel.: + 385 91 46 55 112  
kz@cva.hr

**Ireland**

VIRBAC IRELAND  
McInerney & Saunders  
38, Main Street

**België/Belgique**

VIRBAC Belgium NV  
Esperantolaan 4  
BE-3001 Leuven  
België / Belgique / Belgien  
Tel: +32-(0)16 387 260  
phv@virbac.be

**Κύπρος**

VET2VETSUPPLIES LTD  
Γαλιλαίου 60  
3011 Λεμεσός  
Κύπρος  
Τηλ: + 357 96116730  
info@vet2vetsupplies.com

**Deutschland**

VIRBAC Tierarzneimittel GmbH  
Rögen 20  
23843 Bad Oldesloe  
Deutschland  
Tel: +49-(4531) 805 111

**Eesti**

OÜ ZOOVETVARU  
Uusaru 5  
EE-76505 Saue/Harjumaa  
Eesti  
Tel: + 372 56480207  
pv@zoovet.eu

**Suomi/Finland**

BIOFARM OY  
Yrittäjätie 20  
FI-03600 Karkkila  
Tel: +358-9-225 2560  
haittavaikutukset@biofarm.fi

**Ελλάδα**

VIRBAC ΕΛΛΑΣ ΜΟΝΟΠΡΟΣΩΠΗ Α.Ε.  
13<sup>ο</sup> χλμ Ε.Ο. Αθηνών - Λαμίας  
EL-14452, Μεταμόρφωση  
Τηλ.: +30 2106219520  
info@virbac.gr

**Magyarország**

VIRBAC HUNGARY KFT  
Dózsa György út 84. B épület  
HU-1068 Budapest  
Tel.: +36703387177  
akos.csoman@virbac.hu

**Ísland**

Vistor hf.  
Hörgatún 2,  
IS-210 Garðabær

Swords, Co Dublin  
K67E0A2  
Republic Of Ireland  
Tel: +44 (0)-1359 243243

**Italia**

VIRBAC SRL  
Via Ettore Bugatti, 15  
IT-20142 Milano  
Italia  
Tel: + 39 02 40 92 47 1

**Luxembourg/Luxemburg**

VIRBAC BELGIUM NV  
Esperantolaan 4  
BE-3001 Leuven  
Belgique / Belgien  
Tél/Tel: +32-(0)16 387 260  
info@virbac.be

**Malta**

SEROLF TRADING AGENCY LTD.  
8, Adelaide Cini Street  
Pembroke PBK 1231  
Malta  
Tel: + 35621337231  
info@serolf.com

**Norge**

VIRBAC Danmark A/S  
Profilvej 1  
DK-6000 Kolding  
Danmark  
Tel: + 45 75521244  
virbac@virbac.dk

**Portugal**

VIRBAC de Portugal Laboratórios, Lda.  
Rua do Centro Empresarial  
Edif.13 - Piso 1- Escrit.3  
Quinta da Beloura  
PT-2710-693 Sintra (Portugal)  
Tel: + 351 219 245 020

**Slovenija**

MEDICAL INTERTRADE d.o.o.  
Brodišče 12, 1236 Trzin  
Slovenija  
Tel: + 386 1 2529 113  
farmakovigilanca@medical-intertrade.si

**Sverige**

VIRBAC Danmark A/S Filial Sverige  
Box 1027  
SE-171 21 Solna  
Tel: +45 75521244

Sími: +354 535 7000  
safety@vistor.is

**Lietuva**

OŪ ZOOVETVARU  
Uusaru 5  
EE-76505 Saue/Harjumaa  
Estija  
Tel: + 372 56480207  
pv@zoovet.eu

**Latvija**

OŪ ZOOVETVARU  
Uusaru 5  
EE-76505 Saue/Harjumaa  
Igaunija  
Tel: + 372 56480207  
pv@zoovet.eu

**Nederland**

VIRBAC Nederland BV  
Hermesweg 15  
3771 ND-Barneveld  
Nederland  
Tel: +31-(0)342 427 127  
phv@virbac.nl

**Polska**

VIRBAC Sp. z o.o.  
ul. Puławska 314  
PL-02 - 819 Warszawa  
Polska  
Tel.: + 48 22 855 40 46

**România**

Altius SA  
Str. Zăgăzului nr. 21-25, Corp A, et 8 si 8A  
Ap. A.8.2, sect 1, cod 014261, București,  
Romania  
Tel: + 40 21 310 88 80

**Slovenská republika**

VIRBAC Czech Republic s.r.o.  
Žitavského 496  
156 00 Praha 5  
Česká republika  
Tel.: +420 608 836 529

**United Kingdom (Northern Ireland)**

VIRBAC IRELAND  
McInerney & Saunders  
38, Main Street  
Swords, Co Dublin

virbac@virbac.dk

K67E0A2  
Republic Of Ireland  
Tel: +44 (0)-1359 243243

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

#### **17. Other information**

Hydrocortisone aceponate administered topically accumulates and is metabolised in skin, as suggested by radioactivity distribution studies and pharmacokinetic data. This results in minimal amounts to reach the blood stream. This particularity will increase the ratio between the desired local anti-inflammatory effect in the skin and the undesirable systemic effects.

Hydrocortisone aceponate applications on the skin lesions provide rapid reduction of the skin redness, irritation and scratching while minimising the general effects.